A Study to Learn About How a New Pneumococcal Vaccine Works in Adults
NCT07086677
Recruiting
The purpose of this study is to learn about the safety and tolerability of a pneumococcal vaccine in adults. Participants will receive either: * an experimental PG4 vaccine * a PG4 vaccine comparator * a standard 20vPnC vaccine comparator * placebo. A placebo does not have any medicine in it but looks just like the study medicine. Participants will take part in this study for up to 18 months depending on which group they are assigned to. During this time, the participants will receive up to t... Read More
Gender:
ALL
Ages:
Between 65 years and 84 years
Trial Updated:
08/05/2025
Locations: Orange County Research Center, Lake Forest, California +4 locations
Conditions: Streptococcus Pneumoniae
Register for Updates
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant
NCT02506933
Active Not Recruiting
This randomized phase II trial studies the safety and how well multi-peptide cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) vaccine works in reducing CMV complications in patients previously infected with CMV and are undergoing a donor hematopoietic cell transplant. CMV is a virus that may reproduce and cause disease and even death in patients with lowered immune systems, such as those undergoing a hematopoietic cell transplant. By placing 3 small pieces of CMV deoxyribonucleic acid (DNA)... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/05/2025
Locations: City of Hope Medical Center, Duarte, California +2 locations
Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Chronic Lymphocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Cytomegaloviral Infection, Hodgkin Lymphoma, Lymphadenopathy, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma
Register for Updates
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
NCT05000216
Terminated
This is a randomized, multi-site, adaptive, open-label clinical trial comparing the immune response to different additional doses of COVID-19 vaccine in participants with autoimmune disease requiring IS medications. All study participants will have negative serologic or suboptimal responses (defined as a Roche Elecsys® Anti-SARS-CoV-2 S result ≤200 U/mL) or a low immune response (defined as a Roche Elecsys® Anti-SARS-CoV-2 S result \>200 U/ml and ≤2500 U/mL) to their previous doses of COVID-19 v... Read More
Gender:
ALL
Ages:
2 years and above
Trial Updated:
08/04/2025
Locations: UCLA Medical Center: Division of Rheumatology, Los Angeles, California +28 locations
Conditions: Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Systemic Sclerosis (SSc), Pediatric SLE, Pediatric-Onset Multiple Sclerosis (POMS), Rheumatoid Arthritis (RA), Multiple Sclerosis (MS), Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM)
Register for Updates
Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data
NCT05876377
Active Not Recruiting
This study aims to use vaccination information from state vaccine registries linked with HealthVerity insurance claims for the following: * to measure how effective the Pfizer-BioNTech vaccine is at preventing post-COVID conditions. * to understand characteristics of patients who are receiving COVID-19 vaccines. All patients whose information is kept unidentified in the HealthVerity database are eligible to be included for both aims of this study.
Gender:
ALL
Ages:
6 months and above
Trial Updated:
08/04/2025
Locations: Pfizer, New York, New York
Conditions: SARS-CoV-2, COVID-19, Post-Acute COVID-19 Syndrome
Register for Updates
Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)
NCT03396575
Terminated
The standard of care for children with DIPG includes focal radiotherapy (RT) but outcomes have remained dismal despite this treatment. The addition of oral Temozolomide (TMZ) concurrently with RT followed by monthly TMZ was also found to be safe but ineffective. Recent studies in adults have shown that certain types of chemotherapy induce a profound but transient lymphopenia (low blood lymphocytes) and vaccinating and/or the adoptive transfer of tumor-specific lymphocytes into the cancer patient... Read More
Gender:
ALL
Ages:
Between 3 years and 30 years
Trial Updated:
08/04/2025
Locations: UF Health Shands Children's Hospital, Gainesville, Florida
Conditions: Diffuse Intrinsic Pontine Glioma (DIPG), Brain Stem Glioma
Register for Updates
Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection
NCT06908096
Recruiting
Background: Epstein-Barr virus (EBV) is the primary cause of infectious mononucleosis, commonly known as mono. EBV infects more than 90% of the world s population. Mono can be serious, and it can lead to severe illnesses like cancer and autoimmune diseases. Researchers want to test vaccines that may help prevent EBV and associated diseases. Objective: To test two EBV vaccines: EBV gH/gL/gp42-ferritin and EBV gp350-ferritin. Eligibility: Healthy EBV-negative or EBV-positive people aged 18 to... Read More
Gender:
ALL
Ages:
Between 18 years and 29 years
Trial Updated:
07/31/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: EBV, Epstein-Barr Virus Infection, Infectious Mononucleosis, Mono
Register for Updates
Long-Term PF-06651600 for the Treatment of Alopecia Areata
NCT04006457
Active Not Recruiting
This is a global Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have alopecia areata. Eligible patients from the prior studies B7931005 (NCT02974868) and B7981015 (NCT03732807) will have an opportunity to enroll as well as patients who have not previously participated in either of these studies. The study is open-label and all patients entering the study will receive active study drug... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/28/2025
Locations: The University of Alabama at Birmingham Hosptial Outreach Lab, Birmingham, Alabama +143 locations
Conditions: Alopecia Areata
Register for Updates
Pfizer-BioNTech COVID-19 Vaccine Effectiveness Study - Kaiser Permanente Southern California
NCT04848584
Completed
The primary objective of this study is to determine the vaccine effectiveness of 2 doses of Pfizer-BioNTech BNT162b2 vaccine against COVID-19-associated hospitalization. There will be a large retrospective database study using two parallel study designs: a test-negative case-control design and a retrospective cohort design. VE estimates by various strata and strain type will be conducted.
Gender:
ALL
Ages:
0 years and above
Trial Updated:
07/28/2025
Locations: Kaiser Permanente Southern California, Pasadena, California
Conditions: COVID-19
Register for Updates
Determining the Relationship Between Gut Microbiota and Immune Response to Influenza or COVID-19 Vaccine
NCT05584735
Completed
This study will evaluate the effect of the microorganisms in the gut on how well the flu or COVID-19 vaccine works in people who have a weakened immune system due to inflammatory bowel disease. Participants can expect to be in the study for up to 65 days.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
07/28/2025
Locations: University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
Conditions: Inflammatory Bowel Diseases
Register for Updates
Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1
NCT02775292
Completed
This phase I trial studies the side effects and the best dose of nivolumab when given together with gene-modified T cells and vaccine therapy in treating patients with solid tumors that express the cancer-testes antigen NY-ESO-1 gene AND have spread from where it started to nearby tissue or lymph nodes (locally advanced) or distant organs (stage IV). T cells are a special type of white blood cells (immune cell) that have the ability to kill cancer cells. Nivolumab may block PD-1 which is found o... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
07/28/2025
Locations: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Conditions: Adult Solid Neoplasm, Childhood Solid Neoplasm, Metastatic Neoplasm
Register for Updates
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
NCT04329065
Recruiting
This phase II trial studies the immunologic response and side effects of using the WOKVAC vaccine in combination with chemotherapy and HER2-targeted monoclonal antibody therapy before surgery in treating patients with breast cancer. Vaccines like WOKVAC are made from tumor-associated antigens which may help the body build an effective immune response to kill tumor cells. Chemotherapy drugs, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Register for Updates
COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations
NCT04761822
Completed
Background: Allergic reactions have been reported to occur after vaccination with both the Pfizer-BioNTech COVID-19 Vaccine and Moderna COVID-19 Vaccine. Allergic reactions range from mild to severe and include life- threatening anaphylactic reactions, although no deaths have been reported with either vaccine. This study is designed with two principal aims: * To estimate the proportions of systemic allergic reactions to the Pfizer-BioNTech COVID-19 Vaccine and the Moderna COVID-19 Vaccine in a... Read More
Gender:
ALL
Ages:
5 years and above
Trial Updated:
07/25/2025
Locations: University of Arizona Health Sciences, College of Medicine Tucson, Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Tucson, Arizona +28 locations
Conditions: SARS-CoV Infection, COVID-19, Allergic Reaction, Mast Cell Disorder
Register for Updates